Breast Cancer Clinical Trials in Minnesota

50 recruiting studies across 1 city

Browse by City

All Trials in Minnesota

Phase

Trial	Phase	Sponsor	Dist.
Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials	N/A	Eastern Cooperative Oncology Group	<1 mi
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer	Phase 3	National Cancer Institute (NCI)	<1 mi
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab	Phase 3	Alliance for Clinical Trials in Oncology	<1 mi
Mobile Health for Adherence in Breast Cancer Patients	N/A	ECOG-ACRIN Cancer Research Group	<1 mi
Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors	N/A	NRG Oncology	<1 mi
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer	N/A	SWOG Cancer Research Network	<1 mi
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25	Phase 3	NRG Oncology	<1 mi
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)	Phase 3	NRG Oncology	<1 mi
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity	Phase 3	SWOG Cancer Research Network	<1 mi
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer	Phase 3	SWOG Cancer Research Network	<1 mi
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection	—	Alliance for Clinical Trials in Oncology	<1 mi
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics	—	Wake Forest University Health Sciences	<1 mi
Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer	Phase 3	NRG Oncology	<1 mi
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease	Phase 3	Pfizer	<1 mi
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain	Phase 3	NRG Oncology	<1 mi
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial	Phase 2	National Cancer Institute (NCI)	<1 mi
DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment	Phase 2	QuantumLeap Healthcare Collaborative	<1 mi
A Study of Sigvotatug Vedotin in Advanced Solid Tumors	Phase 1	Seagen, a wholly owned subsidiary of Pfizer	<1 mi
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)	Phase 3	Gilead Sciences	<1 mi
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer	Phase 2	QuantumLeap Healthcare Collaborative	<1 mi
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles	—	Agendia	<1 mi
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors	Phase 1	Normunity AccelCo, Inc.	<1 mi
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer	Phase 1/2	Stemline Therapeutics, Inc.	<1 mi
Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer	Phase 1	Olema Pharmaceuticals, Inc.	<1 mi
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)	Phase 3	Merck Sharp & Dohme LLC	<1 mi
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence	Phase 3	Stemline Therapeutics, Inc.	<1 mi
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer	Phase 3	Canadian Cancer Trials Group	<1 mi
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer	Phase 3	Relay Therapeutics, Inc.	<1 mi
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer	Phase 2	Puma Biotechnology, Inc.	<1 mi
PRE-I-SPY Phase I/Ib Oncology Platform Program	Phase 1	QuantumLeap Healthcare Collaborative	<1 mi
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)	Phase 2/3	Bristol-Myers Squibb	<1 mi
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer	Phase 3	Novartis Pharmaceuticals	<1 mi
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)	Phase 3	AstraZeneca	<1 mi
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation	Phase 3	Sermonix Pharmaceuticals Inc.	<1 mi
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease	—	Adela, Inc	<1 mi
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors	Phase 1	Fate Therapeutics	<1 mi
A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)	Phase 2	Daiichi Sankyo	<1 mi
Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy	Phase 2	BioNTech SE	5 mi
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors	Phase 2	Daiichi Sankyo	5 mi
ASPEN-09: A Study of Evorpacept in Combination With Anti-cancer Therapies in Advanced / Metastatic Malignancies	Phase 1/2	ALX Oncology Inc.	5 mi
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)	—	Exact Sciences Corporation	5 mi
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)	Phase 3	Merck Sharp & Dohme LLC	5 mi
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer	Phase 3	Olema Pharmaceuticals, Inc.	5 mi
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer	Phase 3	AstraZeneca	9 mi
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers	Phase 1	Tizona Therapeutics, Inc	9 mi
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer	Phase 3	Jazz Pharmaceuticals	10 mi
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects	Phase 3	Greenwich LifeSciences, Inc.	11 mi
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)	Phase 1/2	Genmab	13 mi
Reishi Mushroom Extract for Fatigue and/or Arthralgias/Myalgias in Patients With Breast Cancer on Aromatase Inhibitors	Phase 2	Mayo Clinic	34 mi
Endocrine Therapy-Induced Alopecia in Postmenopausal and Premenopausal Female Breast Cancer Patients	—	Mayo Clinic	34 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.